The new RAB002 trial builds on encouraging results from a recent, smaller study of the same vaccine in the UK. Up to 192 healthy people will be randomly assigned to receive one dose of Oxford’s ChAdOx2 RabG vaccine, or one or two doses of a currently licensed rabies vaccine. The study aims to show whether a single dose of the Oxford vaccine has the potential to induce protective immune responses comparable to existing vaccines. Current rabies vaccines are effective but they require multiple doses and they’re too expensive for broad use. This will offer all study participants robust protection against rabies, regardless of how well the Oxford vaccine works.
